Volume - 13 | Issue-1
Volume - 13 | Issue-1
Volume - 13 | Issue-1
Volume - 13 | Issue-1
Volume - 13 | Issue-1
The series of synthesised various-1,2,3-triazole 3a-3f & 5a-5i target compounds described here are designed as analogues for the anti-cancer drug Combretastatin A-4 with varied side substituents. The crystal violet cytotoxicity assay was used to test the anticancer activity of the synthesised compounds against the colon cancer cell line SW480. The findings revealed that all of the synthesised chemicals have a growth inhibiting impact on cancer cells at varying levels of inhibition. Compounds 3a and 5a were found to be the most active, inhibiting cell growth by 77.4% and having a 10 M IC50 value. They were also shown to have relatively minimal cytotoxicity when tested against MDCK (Madin-Darby canine kidney) normal cells